Life Sciences

  • June 18, 2026

    Express Scripts Can't Ditch Meta Wiretap Suit Yet

    A California federal judge refused to dismiss a proposed class action alleging Express Scripts lets Meta secretly read consumers' communications, saying a consumer sufficiently claimed the online pharmacy allowed Meta's unauthorized collection of personal health information.

  • June 18, 2026

    Fertility Chain Beats Suit Alleging Bogus Embryo Test Claims

    A fertility clinic chain has defeated a proposed class action accusing it of deceptively marketing its preimplantation genetic testing, after a Colorado federal judge found none of the patients claimed their own tests were inaccurate or caused a miscarriage or failed pregnancy.

  • June 18, 2026

    Novo Nordisk Sued Over Data Hack Tied To Extortionist Group

    Novo Nordisk was hit with a proposed negligence class action in New Jersey federal court alleging the pharmaceutical giant failed to have adequate data security measures in place to protect sensitive personal health information of patients and employees from being exposed to a cybercriminal extortionist group.

  • June 18, 2026

    Once Dominated By Patent Claims, IP Suits Now More Diverse

    Intellectual property litigation has become more spread out among patents, trademarks and copyrights over the years, as artificial intelligence and e-commerce systems have been drivers of legal matters, according to a new report.

  • June 18, 2026

    Full Fed. Circ. Skips DePuy Bid To Redo Spine Patent Dispute

    The full Federal Circuit won't revisit a panel decision that gave new life to an inventor's suit accusing DePuy Synthes Cos. of infringing his spinal realignment method patents, letting stand the decision that faulted a lower court's handling of expert testimony in the case.

  • June 18, 2026

    RFK Jr. Urges 1st Circ. To Reinstate His Vaccine Advisers

    U.S. Health Secretary Robert F. Kennedy Jr. told the First Circuit a Boston federal judge's decision to freeze his vaccine committee appointments lacks a legal foundation and has left the government paralyzed when it comes to vaccine policy.

  • June 18, 2026

    DEA Picks Only Pot Foes To Join Rescheduling Hearings

    The U.S. Drug Enforcement Administration on Thursday announced its selection of interested parties to participate in upcoming administrative hearings on a proposal to reclassify marijuana to a less restrictive status, each of whom is understood to oppose marijuana rescheduling.

  • June 18, 2026

    Cannabis World Cheers Justices' Gun Rights Ruling

    Cannabis industry stakeholders on Thursday largely applauded the U.S. Supreme Court's unanimous decision finding that a ban on gun ownership for drug users is unconstitutional as applied to a person who regularly uses marijuana.

  • June 18, 2026

    Goodwin, Latham Lead Biotech Kardigan's $400M IPO

    Venture-backed Kardigan Inc., a biotechnology firm developing therapies for cardiovascular diseases, hit the public markets on Thursday after raising $400 million in its initial public offering.

  • June 18, 2026

    Gibson Dunn Hires Ropes & Gray Health Regulatory Atty In DC

    Gibson Dunn & Crutcher LLP has hired a former Ropes & Gray LLP partner who works on a myriad of health regulatory and drug pricing matters, advising pharmaceutical manufacturers, investors and other entities on those issues, the firm announced Thursday.

  • June 18, 2026

    Patent Claims On Novartis Unit Drug Invalid, Del. Judge Says

    A Delaware federal judge has cleared radiopharmaceutical companies of allegations they infringed claims in various patents owned by a French unit of Novartis after finding that all of those claims were invalid.

  • June 18, 2026

    Pharma Co. Says Machine Breakdown Triggered Coverage

    A pharmaceutical company said its insurers improperly denied coverage to fix an eye dropper bottle filling machine, arguing the machine's breakdown caused extensive interruption to business activities that would trigger the policy, according to a complaint removed to California federal court Wednesday.

  • June 18, 2026

    High Court Bars Federal Review Of State Court Appeals

    The U.S. Supreme Court ruled Thursday that a legal doctrine designed to curtail duplicative litigation prevents parties who lose in state court from appealing in federal district court even if the state case is still pending.

  • June 18, 2026

    Justices Allow Gun Rights For Marijuana User

    U.S. Supreme Court justices ruled Thursday that the federal government cannot bar a drug user from owning guns, saying that the prosecution of a Texas man accused of owning a gun while being a marijuana user was inconsistent with the Second Amendment right to bear arms.

  • June 17, 2026

    Eli Lilly Urges Full Fed. Circ. To Scrap Teva's $177M IP Win

    Eli Lilly & Co. urged the full Federal Circuit Wednesday to review a panel ruling that upheld Teva's $177 million jury verdict on headache drug patents, arguing that the panel's decision runs afoul of the justices' Amgen holding and "opens a truck-sized hole in enablement and written description law."

  • June 17, 2026

    Hikma Ruling Raises Patent Pleading Bar Beyond Drug Cases

    The U.S. Supreme Court's decision this month that shut down a patent suit against Hikma Pharmaceuticals USA over a drug using a so-called skinny label could also make it more challenging to plead induced infringement in cases involving other technologies, attorneys say.

  • June 17, 2026

    Grocery Chain Says Aon Put $40M In Opioid Coverage At Risk

    Supermarket chain Giant Eagle on Wednesday hit insurance brokerage firm Aon with claims in Pennsylvania federal court that it jeopardized $40 million in coverage allegedly owed to the chain for settlement and defense costs in opioid litigation.

  • June 17, 2026

    Sen. Committee Clears Drug Disclosure, Biosimilar Bills

    The U.S. Senate Committee on Health, Education, Labor and Pensions on Wednesday cleared two bills for full Senate review, tackling the gap between health and patent oversight agencies, and the need for more interchangeable biosimilars.

  • June 17, 2026

    ITC, Masimo Tell Full Fed. Circ. To Skip Apple Watch Review

    Masimo Corp. and the U.S. International Trade Commission have pushed back on Apple's request for full Federal Circuit rehearing of a panel decision finding an older version of the Apple Watch infringes Masimo's patents, saying Wednesday the case isn't exceptional enough for such scrutiny.

  • June 17, 2026

    Embecta Investor Suit Says Pen Needle Weakness Was Hidden

    Medical device company Embecta Corp. and two of its executives were hit with a proposed class action Wednesday, alleging they misled investors about the sales performance of the company's pen needles, which are often used by patients with diabetes.

  • June 17, 2026

    Del. Court Invalidates Patent Claims In Bioscience Co. Row

    A federal magistrate judge in Delaware on Wednesday found that claims in three molecular labeling patents held by Parse Biosciences Inc. were invalid, months after he found that they weren't infringed by Scale Biosciences Inc.

  • June 17, 2026

    Fed. Circ. Affirms No Block On Stryker Spine Device In IP Fight

    The Federal Circuit on Wednesday agreed with a lower court decision rejecting Boston Scientific Corp.'s request to temporarily block Stryker Corp. from launching a back pain device, saying Stryker made a good enough case that it didn't cause physicians to infringe a patent on the treatment.

  • June 17, 2026

    Glenmark Pharma Beats Suit Over Recalled Cholesterol Drugs

    A New Jersey federal judge Wednesday tossed a proposed class action that accused drugmaker Glenmark Pharmaceuticals of falsely representing that its statin cholesterol drugs were safe and effective despite a recall over its manufacturing practices, saying plaintiff consumers' lack of actual economic or physical injury meant they couldn't sue.

  • June 17, 2026

    Syngenta, Chevron Bids To Move Paraquat Cases Opposed

    Plaintiffs alleging they developed Parkinson's disease from an herbicide asked a Philadelphia judge to block bids by Syngenta and Chevron to move the cases out of the city's mass tort system, arguing that the companies already tried that and failed.

  • June 17, 2026

    HHS Urges DC Court To Toss AbbVie 340B Audit Challenge

    A D.C. federal court should toss a suit by AbbVie challenging the U.S. Department of Health and Human Services' interpretation of who qualifies as a "patient" for audits under the federal 340B drug discount program, HHS said in a motion, arguing the court lacks jurisdiction.

Expert Analysis

  • Accelerated Psychedelic Therapy Pathways Require Caution

    Author Photo

    President Donald Trump's new executive order aiming to accelerate the approval of psychedelic drugs for the treatment of mental health disorders will likely bolster investigational psychedelic therapies, but parties within the psychedelic product supply chain will still need to prepare for potentially burdensome compliance requirements, say attorneys at Morgan Lewis.

  • Heppner Ruling Left AI Privilege Risk For Lawyers Unresolved

    Author Photo

    While a New York federal judge’s recent ruling in U.S. v. Heppner resolved a privilege question surrounding client-side artificial intelligence use, it did not address how to mitigate the risks that can arise when confidential information enters the operative context of an AI system used by an attorney, says Jianfei Chen at Quarles & Brady​​​​​​​.

  • How 10 Years Of Case Law Have Shaped The DTSA

    Author Photo

    As the Defend Trade Secrets Act reaches its 10th anniversary, attorneys at Ropes & Gray examine recent DTSA case law and highlight key takeaways regarding pleading requirements, damages and risk factors.

  • The Ethics And Practicalities Of Representing AI Agents

    Author Photo

    With autonomous artificial intelligence agents now able to take action without explicit instructions from — or the awareness of — their human owners, the bar must confront whether existing frameworks like informed consent and client privilege will be sufficient on the day an AI agent calls seeking counsel, say attorneys at Morrison Cohen.

  • Series

    Speed Jigsaw Puzzling Makes Me A Better Lawyer

    Author Photo

    My passion for speed puzzling — I can complete a 500-piece jigsaw puzzle in under 50 minutes — has sharpened my legal skills in more ways than one, with both disciplines requiring patience, precision and the ability to keep the bigger picture in mind while working through the details, says Tazia Statucki at Proskauer.

  • Opinion

    Congress Should Ax Privacy Bill For Not Shielding Consumers

    Author Photo

    The SECURE Data Act should be rejected because, despite Congress' claims, it would not meaningfully rein in data practices, but instead would weaken enforcement, eliminate stronger protections and prioritize data extraction over consumer protection and accountability, say attorneys at DiCello Levitt.

  • Suit's Dismissal Would Not Settle Gold Card Visa's Legality

    Author Photo

    The government’s recent assertion that the plaintiffs in American Association of University Professors v. Department of Homeland Security lack standing to challenge the Trump administration’s pay-to-play immigration program does not address whether an agency can deem a million-dollar gift evidence of eligibility for immigration benefits carefully defined by Congress, says Jun Li at Reid & Wise.

  • 2 AI Snafus Show Why Attys Can't Outsource Judgment

    Author Photo

    The recent incident involving Sullivan & Cromwell where citations in a filed motion were fabricated by artificial intelligence, as well as a punitive ruling from the Sixth Circuit in U.S. v. Farris, demonstrate that the obligation to supervise AI has belonged and always will belong to lawyers, says John Powell at the Kentucky School Boards Association.

  • Opinion

    Congress Must Repair USPTO's Inter Partes Review Process

    Author Photo

    To challenge recent changes to the inter partes review process issued by the U.S. Patent and Trademark Office, Congress must establish clear statutory guardrails, transparency and meaningful judicial review so that questionable patents receive proper scrutiny, say Sean Tu at the University of Alabama, Arti Rai at Duke University and Aaron Kesselheim at Harvard.

  • Previewing FDA Preapproval Access In Psychedelics EO

    Author Photo

    The second of two pathways for psychedelic drug access outlined in President Donald Trump's recent executive order constitutes an unprecedented expansion of the Right to Try Act, which could fundamentally alter the psychedelic access landscape while presenting significant regulatory, operational and legal challenges, say attorneys at Husch Blackwell.

  • NY's Growing Enviro Reg Framework Will Transform Projects

    Author Photo

    Three closely connected environmental rulemakings in New York state — concerning greenhouse gas reporting, remediation standards and amendments to the State Environmental Quality Review Act — have reached critical stages, and taken together, they will have major impacts on business operations, construction project timelines and transactional risk, say attorneys at Holland & Knight.

  • How 'Spillover' Effects Can Skew AI Securities Class Actions

    Author Photo

    Event study evidence is often central in securities litigation at class certification and beyond, but in an environment where earnings forecasts and statements can have spillover market implications, particularly when concerning artificial intelligence, the task of parsing out the price impact of news requires careful consideration, say Erik Johannesson, Olivia Wurgaft and Nguyet Nguyen at Brattle Group.

  • Previewing FDA National Priority Vouchers In Psychedelics EO

    Author Photo

    President Donald Trump's recent executive order on psychedelic drug access represents a watershed moment in federal drug policy, but its significance lies in two distinct regulatory pathways, the first being the Commissioner's National Priority Vouchers, which offer a significant opportunity to compress U.S. Food and Drug Administration review, say Kimberly Chew at Husch Blackwell and Odette Hauke at Odette Alina.

  • Series

    Playing Magic: The Gathering Makes Me A Better Lawyer

    Author Photo

    The competitive card game Magic: The Gathering offers me a training ground for the strategic thinking skills crucial to litigation, challenging me to adapt to oft-updated rules, analyze text as complicated as any statute and anticipate my opponent’s next moves, says Christopher Smith at Lash Goldberg.

  • Why Product-Based Public Nuisance Claims May Be Waning

    Author Photo

    The Maryland Supreme Court's recent decision in Express Scripts v. Anne Arundel County is the latest in a national trend of rulings rejecting product-based public nuisance claims — but other forms of government litigation against companies that allegedly increase the cost of public services are likely to continue, say attorneys at Simpson Thacher.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.